Fewer than one in 10 people eligible to benefit from GLP-1 drugs like Wegovy have access to them, states the WHO as it issues its inaugural guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidance recognises that obesity is a lifelong illness that can be treated with holistic and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can assist patients in reducing significant body mass, explains the agency.
Weight-Loss Drug Shortage
Even in the present most optimistic outlook, the manufacturing of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation calls on nations and manufacturers to increase access, by approaches like voluntary licensing.
The intellectual property rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a natural hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so users eat less.
People typically begin shedding pounds within a few weeks of beginning the weekly injections.
Studies indicates people may put most of the weight back on after a year of halting the treatment, as their typical food cravings return.
To be overweight or obese elevates your risk for experiencing health problems, such as diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight impacts people in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
